Shining a LIGHT on myeloid cell targeted immunotherapy
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference79 articles.
1. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies;Wei;Proc Natl Acad Sci U S A,2019
2. Phase I/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors;Curigliano;Clin Cancer Res,2021
3. Efficacy and safety of sabatolimab (MBG453) in combination with Hypomethylating Agents (HMAs) in patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study;Brunner;Blood,2020
4. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study;Cho;Lancet Oncol,2022
5. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(.);Niu;Ann Oncol,2022
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. LTBR acts as a novel immune checkpoint of tumor‐associated macrophages for cancer immunotherapy;iMeta;2024-09-04
2. A bioactive soluble recombinant mouse LIGHT promotes effective tumor immune cell infiltration delaying tumor growth;2024-07-30
3. Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses;Cancer Research;2024-02-21
4. Epigenome-Driven Strategies for Personalized Cancer Immunotherapy;Cancer Management and Research;2023-12
5. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists;Frontiers in Immunology;2023-09-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3